Cardiac troponin T is elevated and increases longitudinally in ALS patients

References

• Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237–69.
   PubMed Web of Science ®Google Scholar
• Messner B, Baum H, Fischer P, Quasthoff S, Neumeier D. Expression of messenger RNA of the cardiac isoforms of troponin T and I in myopathic skeletal muscle. Am J Clin Pathol. 2000;114:544–9.
   PubMed Web of Science ®Google Scholar
• Lindberg C, Klintberg L, Oldfors A. Raised troponin T in inclusion body myositis is common and serum levels are persistent over time. Neuromuscul Disord. 2006;16:495–7.
   PubMedGoogle Scholar
• Aggarwal R, Lebiedz-Odrobina D, Sinha A, Manadan A, Case JP. Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. J Rheumatol. 2009;36:2711–4.
   PubMed Web of Science ®Google Scholar
• Cox FM, Delgado V, Verschuuren JJ, Ballieux BE, Bax JJ, Wintzen AR, et al. The heart in sporadic inclusion body myositis: a study in 51 patients. J Neurol. 2010;257:447–51.
   PubMed Web of Science ®Google Scholar
• Rittoo D, Jones A, Lecky B, Neithercut D. Elevation of cardiac troponin T, but not cardiac troponin I, in patients with neuromuscular diseases: implications for the diagnosis of myocardial infarction. J Am Coll Cardiol. 2014;63:2411–20.
   PubMed Web of Science ®Google Scholar
• Wens SC, Schaaf GJ, Michels M, Kruijshaar ME, van Gestel TJ, In ‘t Groen S, et al. Elevated plasma cardiac troponin T levels caused by skeletal muscle damage in Pompe disease. Circ Cardiovasc Genet. 2016;9:6–13.
   PubMed Web of Science ®Google Scholar
• Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, et al. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll Cardiol. 2018;71:1540–9.
   PubMed Web of Science ®Google Scholar
• Mach L, Konecny T, Helanova K, Jaffe AS, Sorenson EJ, Somers VK, et al. Elevation of cardiac troponin T in patients with amyotrophic lateral sclerosis. Acta Neurol Belg. 2016;116:557–64.
   PubMed Web of Science ®Google Scholar
• Casmiro M, Graziani A. Serum troponin T in patients with amyotrophic lateral sclerosis. Acta Neurol Belg. 2019;119:285–8.
   PubMed Web of Science ®Google Scholar
• Rosenbohm A, Schmid B, Buckert D, Rottbauer W, Kassubek J, Ludolph AC, et al. Cardiac findings in amyotrophic lateral sclerosis: a magnetic resonance imaging study. Front Neurol. 2017;8:479.
   PubMed Web of Science ®Google Scholar
• Guo H, Lu M, Ma Y, Liu X. Myoglobin: a new biomarker for spinal and bulbar muscular atrophy? Int J Neurosci. 2020;1–6. doi: https://doi.org/10.1080/00207454.2020.1796660. Epub ahead of print.
   Google Scholar
• Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelsø C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 2002;67:2013–8.
   Google Scholar
• Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One. 2016;11:e0164625.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12–20.
   PubMed Web of Science ®Google Scholar
• Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302–9.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22–e30.
   PubMed Web of Science ®Google Scholar
• Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265:510–21.
   PubMed Web of Science ®Google Scholar
• Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement. 2019;11:730–43.
   Web of Science ®Google Scholar
• Abu-Rumeileh S, Vacchiano V, Zenesini C, Polischi B, de Pasqua S, Fileccia E, et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol. 2020;267:1699–708.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Feneberg E, Halbgebauer S, Witzel S, Verde F, Oeckl P, et al. Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:1–11.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87:628–32.
   PubMed Web of Science ®Google Scholar
• Cleves M. From the help desk: comparing areas under receiver operating characteristic curves from two or more probit or logit models. The Stata J. 2002;2:301–13.
   Web of Science ®Google Scholar
• Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–33.
   PubMed Web of Science ®Google Scholar
• Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32:771–6.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130–9.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:538–48.
   PubMed Web of Science ®Google Scholar
• Gille B, De Schaepdryver M, Goossens J, Dedeene L, De Vocht J, Oldoni E, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2019;45:291–304.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247–57.
   PubMed Web of Science ®Google Scholar
• Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59–e69.
   PubMed Web of Science ®Google Scholar
• Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1103–16.
   PubMed Web of Science ®Google Scholar
• Asai H, Hirano M, Udaka F, Shimada K, Oda M, Kubori T, et al. Sympathetic disturbances increase risk of sudden cardiac arrest in sporadic ALS. J Neurol Sci. 2007;254:78–83.
   PubMed Web of Science ®Google Scholar
• Pavlovic S, Stevic Z, Milovanovic B, Milicic B, Rakocevic-Stojanovic V, Lavrnic D, et al. Impairment of cardiac autonomic control in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:272–6.
   PubMed Web of Science ®Google Scholar
• Pinto S, Pinto A, De Carvalho M. Decreased heart rate variability predicts death in amyotrophic lateral sclerosis. Muscle Nerve. 2012;46:341–5.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamada M, Koumura A, Sakurai T, Hayashi Y, Kimura A, et al. Cardiac sympathetic function in the patients with amyotrophic lateral sclerosis: analysis using cardiac [123I] MIBG scintigraphy. J Neurol. 2013;260:2380–6.
   PubMed Web of Science ®Google Scholar
• Gdynia HJ, Kurt A, Endruhn S, Ludolph AC, Sperfeld AD. Cardiomyopathy in motor neuron diseases. J Neurol Neurosurg Psychiatry. 2006;77:671–3.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Hong YH, Shin JY, Yoon BN, Sohn SY, Park CS, et al. Takotsubo cardiomyopathy in amyotrophic lateral sclerosis. J Neurol Sci. 2017;375:289–93.
   PubMed Web of Science ®Google Scholar
• Lueder V, Melsom TG, Atar MN, Agewall D. S. Amyotrophic lateral sclerosis (ALS), a novel rare cause of elevated plasma troponin T levels. Clin Lab. 2011;57:615–8.
   PubMed Web of Science ®Google Scholar